🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against superbug strains of the bacteria, according to health experts.

An International Challenge

The sexually transmitted infection are escalating globally, with figures suggesting over 82 million new cases annually. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the reality of growing infection rates, escalating drug resistance and the highly restricted available drugs currently available.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Secure Clearance

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists believe that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, was also approved in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This authorization marks a significant shift in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Data and Global Access

As per data detailed in a major medical journal, zoliflodacin eradicated more than 90% of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which uses an injection and a pill. The study enrolled hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Clinicians on the front lines have voiced positive views. Having a one-pill regimen such as this is described as a "revolutionary step" for public health efforts. This is deemed vital to reduce the burden of the illness for people and to halt the transmission of untreatable gonorrhoea worldwide.